Your browser doesn't support javascript.
loading
Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis.
Amani, Behnam; Khodavirdilou, Lida; Rajabkhah, Kourosh; Kardan Moghaddam, Vida; Akbarzadeh, Arash; Amani, Bahman.
Afiliación
  • Amani B; Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran 1416634793, Iran.
  • Khodavirdilou L; Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, United States.
  • Rajabkhah K; Deputy of Research and Technology, Tehran University of Medical Sciences, Tehran 1416634793, Iran.
  • Kardan Moghaddam V; School of Medicine and Dentistry, Griffith University, Queensland, Brisbane 4222, Australia.
  • Akbarzadeh A; Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran 1416634793, Iran.
  • Amani B; Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran 1416634793, Iran. b89amani@yahoo.com.
World J Virol ; 13(1): 88660, 2024 Mar 25.
Article en En | MEDLINE | ID: mdl-38616851
ABSTRACT

BACKGROUND:

Monoclonal antibodies (mAbs) have shown clinical benefits against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several studies have reported the use of bamlanivimab as a promising treatment option for COVID-19.

AIM:

To synthesize the latest evidence for the efficacy and safety of bamlanivimab alone in the treatment of adult patients with COVID-19.

METHODS:

A literature search was conducted in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar using "SARS-CoV-2", "COVID-19", "LY-CoV555", and "Bamlanivimab" keywords up to January 25, 2023. The quality of included studies was assessed using the Cochrane bias tools. The Comprehensive Meta-Analysis software version 3.0 was used to analyze the data.

RESULTS:

A total of 30 studies involving 47368 patients were included. A significant difference was observed between the bamlanivimab and standard of care/placebo groups in terms of mortality rate [risk ratio (RR) = 50, 95% confidence interval (CI) 0.36-0.70], hospitalization rate (RR = 0.51; 95%CI 0.39-0.68), and emergency department (ED) visits (RR = 0.69; 95%CI 0.47-0.99); while the two groups exhibited no significant difference in terms of intensive care unit (ICU) admission (P > 0.05). Compared to other mAbs, bamlanivimab was associated with a higher rate of hospitalization (RR = 1.44; 95%CI 1.07-1.94). However, no significant difference was detected between the bamlanivimab and other mAbs groups in terms of mortality rate, ICU admission, and ED (P > 0.05). The incidence of any adverse events was similar between the bamlanivimab and control groups (P > 0.05).

CONCLUSION:

Although the results suggest the efficacy and safety of bamlanivimab in COVID-19 patients, further research is required to confirm the efficacy of this drug for the current circulating SARS-CoV-2 variants.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: World J Virol Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: World J Virol Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos